Acumen Pharmaceuticals, Inc. repaid and terminated its term loan for approximately $23.3 million on November 5, 2026. It is reducing 52 full-time employees, approximately 90% of its workforce, with approximately $7.75 million in cash restructuring costs.
ABOS · Acumen Pharmaceuticals, Inc.
Substantial doubt about the company's ability to continue as a going concern.
“Based on our current operating plan, we believe there is substantial doubt about our ability to continue as a going concern for at least 12 months following the date of issuance of our unaudited condensed financial statements included in this Quarterly Report on Form 10-Q.”View the 10-Q filed Oct 26, 2026
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Key stats
- Short volume, last session
- 54%
- Last earnings
- Oct 26, 2026
- Latest filing
- 10-Q · Oct 26
- Price history
- Jul 2021 to Nov 2026
Up next
Latest documents
Acumen Pharmaceuticals, Inc. said Phase 2 ALTITUDE-AD missed its primary endpoint at 18 months for both 35 mg/kg and 50 mg/kg doses, plans to cease sabirnetug development, implement cash conservation measures and explore strategic options.
Acumen Pharmaceuticals filed a shelf registration to sell up to $500,000,000 of any combination of common stock, preferred stock, debt securities and warrants, in one or more offerings. The last reported sale price was $1.98 per share on October 23, 2026.
Acumen Pharmaceuticals reported a nine-month net loss of $78.8 million, down from $96.2 million, with cash and marketable securities of $78.6 million as of September 30, 2026. Management concluded there is substantial doubt about the company's ability to continue as a going concern, as cash is expected to fund operations only into early 2027.
Acumen expects to report Phase II Altitude AD top-line results for Soberna Tug in November. Third-quarter net loss was $25.4 million, with approximately $79 million in cash and marketable securities.
Metrics snapshot
Useful current figures from the complete screener profile.
AI Brief
Q2 FY26 earnings call · Aug 12, 2026TL;DR. Acumen reported a narrower Q2 net loss and reduced R&D spending while advancing toward the late-2026 ALTITUDE-AD Phase 2 topline readout for sabirnetug in early Alzheimer's, and nominated two Enhanced Brain Delivery candidates with lead IND targeted for mid-2027; cash of $110.2M is stated to fund operations only into early 2027.
- + R&D expenses fell year-over-year in Q2 2026. new
- + Two Enhanced Brain Delivery candidates were nominated, with lead IND targeted for mid-2027. new
- − Cash runway is stated to extend only into early 2027, ahead of the mid-2027 targeted EBD IND. new
- − Company remains unprofitable with a Q2 2026 loss from operations of $32.6M. new
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ABOS
this stock
Acumen Pharmaceuticals, Inc.
|
$13.49M | -91.2% | — | — | 6.3% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$130.58B | +13.6% | +46.2% | 33.2 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$95.24B | +19.3% | +20.8% | 20.4 | 2.1% |
|
MRNA
Moderna, Inc.
|
$78.90B | +561.2% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$62.17B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 5, 2026
- This year
- 25
Acumen Pharmaceuticals, Inc. repaid and terminated its term loan for approximately $23.3 million on November 5, 2026. It is reducing 52 full-time employees, approximately 90% of its workforce, with approximately $7.75 million in cash restructuring costs.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ABOS | -12.9% | -90.6% | -92.1% | -11.2% | -91.2% |
| SPY | -8.6% | -9.2% | -9.2% | -8.7% | +1.2% |
| vs SPY | -4.3% | -81.4% | -83.0% | -2.5% | -92.3% |